TVTX · Travere Therapeutics
AI read · Good for TVTX
The AI's read
More patients are starting FILSPARI, and many stay on treatment, supporting repeat sales. CEO Eric Dube plans to leave in December, but Bradley is set to join on December 1.
Travere Therapeutics shared its Q3 results, showing product sales over $200 million thanks to strong demand for FILSPARI.
Good for TVTX
Travere said quarterly product sales topped $200 million as demand for FILSPARI grew, supporting a stronger business outlook. CEO Eric Dube will leave in December, but Bradley is set to join on December 1.
Get alerts for TVTX
Follow Travere Therapeutics (TVTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TVTXFree on the App Store and Google Play, or on the web.